Rapid Detection of PML::RARA Fusions in Acute Promyelocytic Leukemia
Author Information
Author(s): Middlezong William, Stinnett Victoria, Phan Michael, Phan Brian, Morsberger Laura, Klausner Melanie, Ghabrial Jen, DeMetrick Natalie, Zhu Jing, James Trisha, Pallavajjala Aparna, Gocke Christopher D., Baer Maria R.
Primary Institution: Johns Hopkins University
Hypothesis
Can a novel amplification-free nanopore sequencing approach improve the detection of PML::RARA fusions in acute promyelocytic leukemia?
Conclusion
The CRISPR/Cas9-enriched nanopore sequencing approach successfully detected typical and atypical PML::RARA fusions in acute promyelocytic leukemia patients.
Supporting Evidence
- CENAS achieved good concordance in detecting PML::RARA fusions compared to standard genetic tests.
- CENAS successfully sequenced breakpoints of typical and atypical PML::RARA fusions.
- The approach allows for real-time sequencing and immediate results, which is critical for patient care.
- CENAS can identify additional genes and genomic regions involved in atypical fusions.
Takeaway
Scientists created a new test that quickly finds a specific gene fusion in leukemia patients, which helps doctors start treatment faster.
Methodology
The study used CRISPR/Cas9 for targeted enrichment and nanopore sequencing with adaptive sampling to detect PML::RARA fusions.
Limitations
The CENAS approach is not suitable for detecting minimal residual disease with low percentages of APL cancer cells.
Participant Demographics
The study included 18 patients, with a median age of 44 years, consisting of 10 women and 8 men.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website